Advanced Medical Solutions Group (LSE:AMS) Research & Development: £0.0 Mil (TTM As of Dec. 2025)


LSE:AMS Advanced Medical Solutions Group PLC LSE:AMS
89 GF Score
Price £2.79
GF Value £3.69
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Advanced Medical Solutions Group Research & Development?

Advanced Medical Solutions Group LSE:AMS +16.04% 89 Research & Development is £0.0 Mil as of Dec. 2025. GuruFocus rates LSE:AMS with a GF Score™ of 89/100 and a GF Value™ of £3.69 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Advanced Medical Solutions Group's Research & Development for the six months ended in Dec. 2025 was £0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was £0.0 Mil.

Advanced Medical Solutions Group  (LSE:AMS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Advanced Medical Solutions Group Research & Development Related Terms

Advanced Medical Solutions Group Research & Development Historical Data

* Premium members only.

The historical data trend for Advanced Medical Solutions Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Medical Solutions Group Research & Development Chart

Advanced Medical Solutions Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Advanced Medical Solutions Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:AMS
89GF Score
Advanced Medical Solutions Group PLC LSE:AMS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Medical Solutions Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.0 Mil mean?
Advanced Medical Solutions Group (LSE:AMS) has a Research & Development of £0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Advanced Medical Solutions Group and its competitors.
Is Advanced Medical Solutions Group's Research & Development too high?
Advanced Medical Solutions Group's current Research & Development is £0.0 Mil. Overall, Advanced Medical Solutions Group has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Research & Development compare to ISRG and BDX?
Advanced Medical Solutions Group's Research & Development of £0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Advanced Medical Solutions Group and its competitors. Advanced Medical Solutions Group's current Research & Development is £0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (LSE:AMS) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.69, compared to a current price of £2.79 — trading 24.5% below its estimated fair value. The current Research & Development is £0.0 Mil. Advanced Medical Solutions Group's overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Advanced Medical Solutions Group (LSE:AMS), the current Research & Development is £0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Advanced Medical Solutions Group (LSE:AMS) Overvalued in 2026?

Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued. The current stock price of £2.79 is trading 24.5% below its estimated GF Value™ of £3.69. GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.

Key valuation signals for LSE:AMS:

  • Research & Development: £0.0 Mil
  • GF Value™: £3.69 vs. price of £2.79 (24.5% below fair value)
  • GF Score™: 89/100 with 6 warning signs

No single metric tells the full story. See the LSE:AMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Advanced Medical Solutions Group Business Description

Other Exchanges AMSl:UKAQA:Germany
Address Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
89GF Score

Get the complete analysis for LSE:AMS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£2.79
Price
£3.69
GF Value